Learn more

SPHINGOTEC GMBH

Overview
  • Total Patents
    161
  • GoodIP Patent Rank
    11,592
  • Filing trend
    ⇧ 10.0%
About

SPHINGOTEC GMBH has a total of 161 patent applications. It increased the IP activity by 10.0%. Its first patent ever was published in 2005. It filed its patents most often in United States, EPO (European Patent Office) and China. Its main competitors in its focus markets measurement, pharmaceuticals and biotechnology are BERGMANN ANDREAS, STRUCK JOACHIM and BRAHMS AG.

Patent filings per year

Chart showing SPHINGOTEC GMBHs patent filings per year from 1900 to 2020

Focus industries

Top inventors

# Name Total Patents
#1 Bergmann Andreas 141
#2 Melander Olle 65
#3 Ng Leong 16
#4 Andreas Bergmann 9
#5 Voors Adriaan 8
#6 Olle Melander 5
#7 Ernst Andrea 3
#8 Adriaan Voors 2
#9 Sparwasser Andrea 1
#10 De Wildt Saskia 1

Latest patents

Publication Filing date Title
WO2021028582A1 A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
WO2020128073A1 Selenoprotein p in heart failure
CN111902721A Use of adrenomedullin and anti-adrenomedullin conjugates for the diagnosis and/or prognosis of dementia for the treatment or prevention of dementia
AU2018356370A1 Selenoprotein P for prediction of a first cardiovascular event
CN110678757A Methods of diagnosing or monitoring renal function or diagnosing renal dysfunction
AU2017294549A1 Adrenomedullin for assessing congestion in a subject with acute heart failure
EP3339324A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
US2017052203A1 Adrenomedullin assays and methods for determining mature adrenomedullin
EP3309550A1 Method for the detection of apolipoprotein e4
SG11201708655UA A method for predicting the risk of incidence of chronic kidney disease
CN107430135A A kind of method for the risk of obesity for predicting subject
EP3002589A1 A method for stratifying a female subject for hormone replacement therapy
SG11201702053TA Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
CN105765385A Method for predicting the risk of getting major adverse cardiac event
CN105102985A Adrenomedullin to guide therapy of blood pressure decline
US2015346207A1 Method for predicting the risk of getting cancer or diagnosing cancer in a subject
CN107991501A Predicting marker of the fasting levels of growth hormone as cardiovascular risk
CN110221071A Prediction female subject cancer stricken risk or the method for diagnosing its cancer
RU2707303C1 Diagnostic or monitoring method of renal function or diagnosis of renal dysfunction
RS55804B1 Adrenomedullin assays and methods for determining mature adrenomedullin